Mirati Therapeutics Inc (NASDAQ: MRTX), a clinical stage targeted oncology company, announced yesterday that it has named Daniel R Faga as its new executive vice president, chief operating officer.

Faga is to report directly to Charles M Baum, MD, PhD, president and chief executive officer. In the new role, he will be responsible for a broad range of operational areas including but not limited to corporate strategy, finance, legal, program management and investor relations & corporate affairs.

Faga is an executive with around 20 years of biopharma and investment banking experience in the life sciences sector. He also has extensive experience in developing and executing biopharma growth strategies, with expertise in corporate strategy, mergers and acquisitions and partnering on more than USD50bn in biopharma transactions. He was formerly the chief business officer at Spark Therapeutics Inc, a broad operating position he held since 2016. Prior to joining Spark Therapeutics, he was a managing director at Centerview Partners, from 2009 – 2016, where he served as a founding member of their healthcare advisory practice. Prior to Centerview Partners, Faga held additional investment banking and management consulting roles advising biotech and pharmaceutical companies.